Sugi Predict

Sugi Predict / Compounds / SCHEMBL20743006

SCHEMBL20743006

SCHEMBL20743006

CC(C)c1cc(F)cc(-c2cncnc2)c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.40
▸ ALOX5AP P20292 2/20 0.35
▸ FEN1 P39748 2/20 0.35
▸ RPS6KA3 P51812 1/20 0.34
▸ BACE1 P56817 3/20 0.33
▸ CTSD P07339 2/20 0.33
▸ BACE2 Q9Y5Z0 2/20 0.33
▸ AKR1C3 P42330 1/20 0.33
▸ AKR1C2 P52895 1/20 0.33
▸ P2RX3 P56373 2/20 0.32
▸ P2RX2 Q9UBL9 2/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ HCK P08631 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ MTOR P42345 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20743758 0.86 DYRK1A (0.37) JAK2ALOX5APFEN1RPS6KA3PIK3CA
SCHEMBL20609816 0.82 JAK2 (0.45) JAK2RPS6KA3BACE1AKR1C3AKR1C2
SCHEMBL20744370 0.82 CYP11B1 (0.37) JAK2RPS6KA3BACE1BACE2PIK3CA
SCHEMBL20743855 0.81 IKBKB (0.43) RPS6KA3AKR1C3AKR1C2NLRP3
SCHEMBL20754791 0.80 CYP11B1 (0.41) —
SCHEMBL20743713 0.77 MET (0.34) ALOX5APFEN1MET
SCHEMBL20754892 0.77 METAP2 (0.37) JAK2ALOX5APFEN1AKR1C3AKR1C2
SCHEMBL20754515 0.76 ALOX5AP (0.42) ALOX5APFEN1PIK3CDPIK3CAPIK3CB
SCHEMBL20743756 0.76 TDO2 (0.44) ALOX5APFEN1RPS6KA3P2RX3P2RX2
SCHEMBL19474940 0.74 HRH4 (0.35) RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 — — CN disclosed
US-11613542-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2023-03-28 — — US disclosed
US-11542255-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2023-01-03 — — US disclosed
US-11542255-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2023-01-03 — — US disclosed
US-20210130359-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2021-05-06 — — US disclosed
US-20210130329-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2021-05-06 — — US disclosed
US-20210130359-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2021-05-06 — — US disclosed
US-20210130329-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2021-05-06 — — US disclosed
US-20210122739-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2021-04-29 — — US disclosed
US-20210122739-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2021-04-29 — — US disclosed
EP-3668842-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS Inflazome Limited (IE) 2020-06-24 — — EP disclosed
EP-3668862-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2020-06-24 — — EP disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034692-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034692-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034688-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034690-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034688-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034690-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122739-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, PYCARD, NOD1 JAK2 2297/4885ALOX5AP 1859/4885FEN1 4747/4885
US-11542255-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors NLRP3, NOD1, PYCARD JAK2 2226/4885ALOX5AP 3568/4885FEN1 4252/4885
US-20210130359-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 JAK2 1997/4885ALOX5AP 3723/4885FEN1 4178/4885
US-20210130329-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS NLRP3, NOD1, PYCARD JAK2 2226/4885ALOX5AP 3568/4885FEN1 4252/4885
US-11613542-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors NLRP3, NOD1, NLRP1 JAK2 1997/4885ALOX5AP 3723/4885FEN1 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.